¿Cómo paga?

Cómo pagar lo menos posible

No se vende

Flumadine ya no se vende con receta.

Compare todas las opciones

De marca

Flumadine ya no se vende con receta.

No se vendeYa no se vende

Genérico autorizado

Antes se vendía uno, pero ya no.

No se vendeYa no se vende

Genérico regular

La FDA aprobó un genérico, pero todavía no está en las farmacias.

No se vendeAún no en farmacias

Para qué se usa

Lo que dice la etiqueta de la FDA (en inglés)

Rimantadine hydrochloride tablet is indicated for the prophylaxis and treatment of illness caused by various strains of influenza A virus in adults (17 years and older).

Rimantadine hydrochloride tablet is indicated for prophylaxis against influenza A virus in children (1 year to 16 years of age).

Prophylaxis

In controlled studies of children (1 year to 16 years of age), healthy adults (17 years and older), and elderly patients (65 years of age and older), rimantadine hydrochloride has been shown to be safe and effective in preventing signs and symptoms of infection caused by various strains of influenza A virus. Since rimantadine hydrochloride does not completely prevent the host immune response to influenza A infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically-related viruses. Following vaccination during an influenza outbreak, rimantadine hydrochloride prophylaxis should be considered for the 2 to 4 week time period required to develop an antibody response. However, the safety and effectiveness of rimantadine hydrochloride prophylaxis have not been demonstrated for longer than 6 weeks.

Treatment

Rimantadine hydrochloride therapy should be considered for adults (17 years and older) who develop an influenza-like illness during known or suspected influenza A infection in the community. When administered within 48 hours after onset of signs and symptoms of infection caused by influenza A virus strains, rimantadine hydrochloride has been shown to reduce the duration of fever and systemic symptoms.

The following points should be considered before initiating treatment or prophylaxis with rimantadine hydrochloride:

  • Rimantadine hydrochloride is not a substitute for early vaccination on an annual basis as recommended by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices.
  • Influenza viruses change over time. Emergence of resistance mutations could decrease drug effectiveness. Other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. Prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use rimantadine hydrochloride.

Fuente: la etiqueta de la FDA de Rimantadine Hydrochloride (Amneal Pharmaceuticals of New York LLC), 31 de diciembre de 2023. Etiqueta completa en DailyMed